Learning objectives: Define the clinical benefit associated with CYP2C19 genotype-guided antiplatelet therapy.
Discuss the opportunities for improving pain management with opiates based on CYP2D6 phenotype.
Tuesday, October 31, 2017 - 12:00pm to 1:00pm
Julie A. Johnson, Pharm.D.
Chicago, IL 60637
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation